Kenneth R. Lynn
Plus aucun poste en cours
Profil
Kenneth R.
Lynn served as Chairman & CEO at Cortech, Inc. and as VP & General Counsel at U.S.
Bioscience, Inc. He also held senior positions at Valentis, Inc., RxKinetix, Inc., and NewLink Genetics Corp.
Additionally, he was Corporate Counsel at Marion Laboratories and Executive VP at Kansas Technology Enterprise Corp.
Lynn's education includes an MBA from Rockhurst University, a graduate degree from the University of Kansas, and an undergraduate degree from Washburn University.
Anciens postes connus de Kenneth R. Lynn
| Sociétés | Poste | Fin |
|---|---|---|
| LUMOS PHARMA, INC. | Corporate Officer/Principal | 27/06/2012 |
Kansas Technology Enterprise Corp.
 Kansas Technology Enterprise Corp. Investment ManagersFinance Founded in 1987, the Kansas Technology Enterprise Corporation is a private/public partnership established by the state of Kansas to promote technology based economic development. They are located in Topeka, Kansas | Corporate Officer/Principal | 28/02/2008 |
| Kauffman Innovation Network, Inc. | President | 01/01/2006 |
RxKinetix, Inc.
 RxKinetix, Inc. Pharmaceuticals: MajorHealth Technology RxKinetix, Inc. develops new therapeutic drugs. The company uses proven pharmaceuticals and proprietary polymer-based drug delivery technologies and creates new drugs or enhances existing drugs. It also develops drugs for oral mucositis and other supportive care oncology conditions. RxKinetix was founded in 1996 and is located in Boulder, CO | Conseiller Juridique Général | 01/01/2002 |
Valentis, Inc.
 Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Conseiller Juridique Général | 01/01/2000 |
Formation de Kenneth R. Lynn
| Rockhurst University | Masters Business Admin |
| University of Kansas | Graduate Degree |
| Washburn University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
| Cortech, Inc. | Health Technology |
U.S. Bioscience, Inc.
 U.S. Bioscience, Inc. BiotechnologyHealth Technology U.S. Bioscience, Inc. is a pharmaceutical company specializing in the development and commercialization of products for patients with cancer and AIDS and allied infections. The company has three products on the market. In addition to its headquarters, U.S. Bioscience has a manufacturing facility located in Nijmegen, The Netherlands, an analytical laboratory in Exton, PA, and a subsidiary near London to coordinate clinical trials in Europe. U.S. Bioscience, Inc. is headquartered in West Conshohocken, PA. | Health Technology |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
RxKinetix, Inc.
RxKinetix, Inc. Pharmaceuticals: MajorHealth Technology RxKinetix, Inc. develops new therapeutic drugs. The company uses proven pharmaceuticals and proprietary polymer-based drug delivery technologies and creates new drugs or enhances existing drugs. It also develops drugs for oral mucositis and other supportive care oncology conditions. RxKinetix was founded in 1996 and is located in Boulder, CO | Health Technology |
Kansas Technology Enterprise Corp.
Kansas Technology Enterprise Corp. Investment ManagersFinance Founded in 1987, the Kansas Technology Enterprise Corporation is a private/public partnership established by the state of Kansas to promote technology based economic development. They are located in Topeka, Kansas | Finance |
| Marion Laboratories | Distribution Services |
| Kauffman Innovation Network, Inc. |
